论文部分内容阅读
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with major morbidity and mortality.Therapeutic management is difficult,due to lack of conclusive data and individual disease progression.High-dose UDCA was used for years as a pharmacotherapeutic agent to prevent disease progression,based on a positive trend in pilot studies,but has recently been proven to have a negative effect in advanced disease.Immunosuppressants might be useful in patients with overlap syndromes.Dominant bile duct stenoses should be treated endoscopically,and cholangiocellular carcinoma (CCC) still remains a therapeutic challenge in PSC patients.Early diagnosis of CCC must be improved and new strategies such as neoadjuvant radiochemotherapy with subsequent liver transplantation in selected patients are further options to be considered.
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with major morbidity and mortality. Therapeutic management is difficult, due to lack of conclusive data and individual disease progression. High-dose UDCA was used for years as a pharmacotherapeutic agent to prevent disease progression , based on a positive trend in pilot studies, but has recently proven to have a negative effect in advanced disease. Immunosuppressants might be useful in patients with overlap syndromes. Dominant bile duct stenoses should be treated endoscopically, and cholangiocellular carcinoma (CCC) still remains a therapeutic challenge in PSC patients. Complete diagnosis of CCC must be improved and new strategies such as neoadjuvant radiochemotherapy with subsequent liver transplantation in selected patients are further options to be considered.